1. Kharab R, Sharma PC, Yar MS. Pharmacological significance of triazole scaffold J. Enzyme Inhib Med Chem. 2010;26:1-21. [DOI via Crossref] [Pubmed] | | 2. Chawla R, Sahoo U, Arora A, Sharma PC, Vijayaraj R. Microwave assisted synthesis of some novel 2-pyrazoline derivatives as possible antimicrobial agents. Acta Pol Pharm Drug Res. 2010;67(1):55-61. | | 3. Choudhury D, Talukdar AD, Maurya AP, Choudhury MD, Dhar Chanda D, Chakravarty A, et al. Contribution of efflux pumps in fluroquinolone resistance in multi-drug resistant nosocomial isolates of Pseudomanas aeruginosa from a tertiary referral hospital in north east India. Indian J Med Microbiol. 2015;33(1):84-6. [DOI via Crossref] [Pubmed] | | 4. Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated uinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. Antimicrob Agents Chemother. 2007;51:1223-7. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 5. Sharma PC, Jain A, Jain S, Pahwa R, Yar MS. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. J Enzyme Inhib Med Chem. 2010;25(4):577-89. [DOI via Crossref] [Pubmed] | | 6. Sharma PC, Saneja A, Jain S. Norfloxacin: a therapeutic review. Int J Chem Sci. 2008;6(4):1702-13. | | 7. Sharma PC, Jain A, Jain S. Therapeutic perspectives of fluoroquinolone antibacterials: an update. Proceedings of the 1st Rashtriya Yuva Vaigyanik Sammelan. Kurukshetra: NIT, November 28-30, 2008. pp. 234-9. | | 8. Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353-69. [DOI via Crossref] [Pubmed] | | 9. Sousa J, Alves G, Fortuna A, Falcão A. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf. 2014;9(2):89-105. [DOI via Crossref] [Pubmed] | | 10. Rifenburg RP, Paladino JA, Bhavnani SM, Haese DD, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm. 1999;56(21):2217-23. [Pubmed] | | 11. Hooper D. Quinolones. In: Mandell GL, Bennett JE, Mandell DR (Eds.), Douglas and Bennett’s Principles and Practice of Infectious Disease, 5th ed. Philadelphia, PA: Churchill Livingstone, 2000. pp. 404-23. | | 12. In Recent Years, Bulk Drugs and Intermediates Ciprofloxacin Market Analysis. Available at: http://www.articlesbase.com/non-profitorganizations-articles/in-recent-years-bulk-drugs-and-intermediatesciprofloxacin-market-analysis-3498636.html [accessed April 15, 2015]. | | 13. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21. [DOI via Crossref] [Pubmed] | | 14. Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clin Ther. 1999;21(10):1788-96. Erratum in: Clin Ther. 1999;21(12):2186. [DOI via Crossref] | |
|
|